TriangleHEALTH PROFESSIONAL · SOURCE READING
Chimeric antigen receptor (CAR) T-cell therapy
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Autologous T cells can be modified by viral vectors to incorporate antigen receptor specificity for the B-cell antigen CD19 and then infused into previously treated patients.[9] A dramatic response lasting 6 months has prompted larger trials of this concept. Ongoing clinical trials are testing the concept of T cells directed at CD19 with engineered CAR T cells.[10-12]
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice